Acadia Pharmaceuticals (ACAD) announced that Catherine Owen Adams has succeeded Steve Davis as CEO and joined the Acadia Board of Directors. Most recently, she served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMY), where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Stoke Therapeutics (STOK) Stock Surges on Potential Genetic Treatment Breakthrough
- NY Times says Acadia holding people against will to maximize insurance payouts
- Biotech Alert: Searches spiking for these stocks today
- Acadia Pharmaceuticals price target lowered to $23 from $30 at Citi
- Acadia Pharmaceuticals price target lowered to $28 from $37 at Cantor Fitzgerald